All In Biotech

Drug Trial Radar · NCT04469465

Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

A Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 Inhibitor (Eculizumab or Ravulizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Evident Extravascular Hemolysis (EVH)

Last checked: Nov 20, 2026Latest source record: May 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

86

Actual

Start

Dec 16, 2020

Primary completion

Jun 29, 2022

Study completion Jan 16, 2024

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to evaluate the efficacy of danicopan as add-on therapy to a complement component 5 (C5) inhibitor (eculizumab or ravulizumab) in participants with PNH who have clinically evident EVH.

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • DanicopanDrug

    Oral tablet

  • PlaceboDrug

    Oral tablet

  • C5 InhibitorDrug

    Participants will continue to receive their ongoing C5 inhibitor (eculizumab or ravulizumab) therapy according to their usual dose and schedule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hgb at Week 12Time frame: Baseline, Week 12

Locations

62 sites in 18 countries. Site status is shown where the registry gives one.

  • Research Site

    Los Angeles, California

  • Research Site

    Weston, Florida

  • Research Site

    Chicago, Illinois

  • Research Site

    Kalamazoo, Michigan

  • Research Site

    New York, New York

  • Research Site

    Dallas, Texas

  • Research Site

    Milwaukee, Wisconsin

  • Research Site

    Belém, Brazil

  • Research Site

    Curitiba, Brazil

  • Research Site

    Goiânia, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Rio de de Janeiro, Brazil

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Brno, Czechia

  • Research Site

    Lille, France

  • Research Site

    Paris, France

  • Research Site

    Pessac, France

  • Research Site

    Pierre-Bénite, France

  • Research Site

    Ulm, Germany

  • Research Site

    Athens, Greece

  • Research Site

    Thessaloniki, Greece

  • Research Site

    Haifa, Israel

  • Research Site

    Jerusalem, Israel

  • Research Site

    Avellino, Italy

  • Research Site

    Bassano del Grappa, Italy

  • Research Site

    Florence, Italy

  • Research Site

    Milan, Italy

  • Research Site

    Reggio Calabria, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Bunkyō City, Japan

  • Research Site

    Fukuoka, Japan

  • Research Site

    Kashiwa-shi, Japan

  • Research Site

    Kyoto, Japan

  • Research Site

    Nagakute-shi, Japan

  • Research Site

    Ogaki-shi, Japan

  • Research Site

    Osaka, Japan

  • Research Site

    Sayama, Japan

  • Research Site

    Shibuya-ku, Japan

  • Research Site

    Tanabe-shi, Japan

  • Research Site

    Toyoake-shi, Japan

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.